In contrast, retatrutide, currently undergoing clinical studies, shows promise for enhanced effectiveness, potentially offering up to a 24.2% reduction in mass over 48 weeks
[DOI] [Google Scholar] Guryanov I., Bondesan A., Visentini D., Orlandin A., Biondi B., Toniolo C., Formaggio F., Ricci A., Zanon J., Cabri W
LegitScript certification surfaced in the flow
A report from PricewaterhouseCoopers found that GLP-1 drugs drove a disproportionate share of the $50 billion hike in pharmacy spending in 2024 (up from a $20 billion increase in 2023)
The data show clear changes in food spending following adoption, said study author Sylvia Hristakeva, an assistant professor at Cornells SC Johnson College of Business, in a statement from the university
The findings of these studies, along with the proven benefits of GLP-1 medications and low overall prevalence of NAION, should be considered together when counseling patients on the use of these medications, the authors concluded